Dynavax Technologies
DVAX
$11.20
Share price
1.08%
Change (1 day)
-5.56%
Change (1 year)
Categories
Revenue for Dynavax Technologies (DVAX)
Revenue in 2023 (TTM): $0.65 B
According to Dynavax Technologies 's latest financial reports the company's current revenue (TTM) is $0.65 B. In 2022 the company made a revenue of $0.72 B an increase over the years 2021 revenue that were of $0.43 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Dynavax Technologies from 2004 to 2023
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2023 (TTM) | $0.65 B | -9.28% |
| 2022 | $0.72 B | 64.45% |
| 2021 | $0.43 B | 844% |
| 2020 | $46.55 M | 32.18% |
| 2019 | $35.21 M | 329.6% |
| 2018 | $8.19 M | 2407.03% |
| 2017 | $0.32 M | -97.04% |
| 2016 | $11.04 M | 172.67% |
| 2015 | $4.05 M | -63.29% |
| 2014 | $11.03 M | -1.95% |
| 2013 | $11.25 M | 15.82% |
| 2012 | $9.71 M | -55.06% |
| 2011 | $21.61 M | -9.75% |
| 2010 | $23.95 M | -40.6% |
| 2009 | $40.31 M | 8.69% |
| 2008 | $37.09 M | 163.21% |
| 2007 | $14.09 M | 190.76% |
| 2006 | $4.84 M | -66.93% |
| 2005 | $14.65 M | -1.06% |
| 2004 | $14.81 M |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $92.95 B | 14,077.81% | 🇺🇸 USA |
 Amgen AMGN | $26.19 B | 3,894.72% | 🇺🇸 USA |
 Biogen BIIB | $10.10 B | 1,441.24% | 🇺🇸 USA |
 Gilead Sciences GILD | $27.04 B | 4,024.82% | 🇺🇸 USA |
 Merck MRK | $57.86 B | 8,726.66% | 🇺🇸 USA |
 AstraZeneca AZN | $43.83 B | 6,586.69% | 🇬🇧 UK |
 GlaxoSmithKline GSK | $34.70 B | 5,192.89% | 🇬🇧 UK |
 Agenus
AGEN | $98.02 M | -85.05% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | $14.92 B | 2,176.64% | 🇮🇱 Israel |